In Dec 2021, Cyrus Biotechnology announced an $18M financing and the firm's acquisition of the company Orthogonal Biologics. Indicated was intent to form an Integrated software-driven pre-clinical-stage drug discovery firm: Cyrus Biotechnology and Orhtogonal Biologics ________ Original write-up: To accelerate basic research in biotech, pharma, and industrial biotechnology, Cyrus Biotechnology Inc develops software for protein structure prediction and protein design. The company's software is based primarily on the Rosetta molecular modeling and design toolkit first developed at the lab of co-founder David Baker. The firm's main product is Cyrus Bench, an easy-to-use version of the Rosetta molecular modeling and protein design software package. The technology has applications in protein structure prediction, protein-ligand docking, protein-protein docking, antibody modeling, and structure modeling with experimental information (X-ray, NMR, Cryo-EM).
